Ricardo Restrepo-Jaramillo, MD
Pulmonary Disease · Tampa, FLNPI 1295994952
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $439,177 of the $554,525 with a category attached, or 79.2%. 24 manufacturers reported payments, led by United Therapeutics Corporation at 54.4% of the total. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 662 payments — averaging $837.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$301K
- Actelion Pharmaceuticals US, Inc.$144K
- Bayer$60K
- Merck$42K
- Chiesi USA, Inc.$4K
- Abiomed$438
- plus $2K from 18 others
Across 315 payments — averaging $7596.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.3M
- United Therapeutics Corporation$828K
- Insmed, Inc.$144K
- Novartis$30K
- Actelion Pharmaceuticals, Ltd$29K
- Bayer$28K
- plus $22K from 2 others
What the payments were for
- Consulting fees$58,71411%
- Speaking & faculty fees$439,17779%
- Travel & lodging$35,5756%
- Food & beverage$20,5384%
- Education$5210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 351 | $301,429 |
| Actelion Pharmaceuticals US, Inc. | 160 | $144,424 |
| Bayer | 52 | $60,379 |
| Merck | 43 | $41,752 |
| Chiesi USA, Inc. | 5 | $4,063 |
| Abiomed | 4 | $438 |
| Boehringer Ingelheim | 8 | $434 |
| La Jolla Pharmaceutical Company | 4 | $364 |
| Astellas Pharma US Inc | 6 | $313 |
| Innovation Technologies Inc | 1 | $174 |
| Sandoz | 4 | $146 |
| Johnson & Johnson(2 entities) | 5 | $108 |
| ANI Pharmaceuticals, Inc. | 3 | $98 |
| Liquidia Technologies, Inc. | 1 | $81 |
| Shionogi Inc | 3 | $57 |
| Vertex | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $46 |
| Mylan Specialty L.p. | 2 | $43 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Melinta Therapeutics, LLC | 1 | $25 |
| Gilead | 1 | $23 |
| Atricure, Inc. | 1 | $20 |
| Getinge USA Sales, LLC | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$554,525 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 458 | $5,739,399 |
| Tyvaso DpiTreprostinil | 207 | $4,773,816 |
| AdempasRiociguat | 299 | $4,171,604 |
| UptraviSelexipag | 151 | $3,746,206 |
| Orenitram ErTreprostinil Diolamine | 206 | $1,968,925 |
| WinrevairSotatercept-Csrk | 31 | $557,856 |
| LetairisAmbrisentan | 39 | $501,690 |
| Ambrisentan | 167 | $414,940 |
| OpsynviMacitentan/Tadalafil | 32 | $398,835 |
| AdcircaTadalafil | 24 | $210,270 |
| Tadalafil | 124 | $137,394 |
| Sildenafil Citrate | 425 | $71,623 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $27,631 |
| Midodrine Hcl | 63 | $9,827 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,616 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Opsynvi | $144,424 | $9,884,440641 claims |
| BayerAdempas | $60,379 | $4,171,604299 claims |
| MerckWinrevair | $41,752 | $557,85631 claims |
| GileadLetairis | $23 | $501,69039 claims |
| United Therapeutics CorporationAdcirca | $301,429 | $210,27024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Tampa
- Mark RumbakTampa$528K
- Domenick ReinaTampa$469K
- Michael AlvarezTampa$202K
- Nirav PatelTampa$105K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Jose Soto SotoJacksonville$504K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.